DYRK1A, AMKL, and Down syndrome

http://www.ncbi.nlm.nih.gov/pubmed/22354166

J Clin Invest. 2012 Mar 1;122(3):807-10. doi: 10.1172/JCI62372. Epub 2012 Feb 22.
DYRK1A in Down syndrome: an oncogene or tumor suppressor?
Birger Y, Izraeli S.

Abstract
Children with Down syndrome (DS) have a markedly increased risk of developing acute megakaryoblastic leukemia (AMKL) and acute lymphoblastic leukemia compared with that of children without DS. Despite recent breakthroughs, it is not clear which genes on chromosome 21, the chromosome that is trisomic in individuals with DS, cause this predisposition. In this issue of the JCI, Malinge et al. report their loss- and gain-of-function experiments in mouse and human cells that show that increased expression of the kinase encoded by the chromosome 21 gene DYRK1A suppresses the nuclear factor of activated T cells pathway and promotes AMKL. Interestingly, the same protein has been suggested to contribute to the reduced risk of epithelial cancers in adults with DS, leading to the possibility that it could be proleukemic in children and antitumorigenic in adults.